A number of other research firms have also issued reports on MYL. Leerink Swann set a $45.00 target price on shares of Mylan and gave the company a buy rating in a research note on Saturday, October 1st. Wells Fargo & Co. set a $44.00 target price on shares of Mylan and gave the company a hold rating in a research note on Saturday, October 1st. Zacks Investment Research upgraded shares of Mylan from a hold rating to a buy rating and set a $49.00 target price on the stock in a research note on Tuesday, July 5th. Argus set a $55.00 target price on shares of Mylan and gave the company a buy rating in a research note on Thursday, September 22nd. Finally, TheStreet lowered shares of Mylan from a buy rating to a hold rating in a research note on Wednesday, September 28th. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $53.49.
Mylan (NASDAQ:MYL) opened at 37.88 on Monday. Mylan has a one year low of $35.58 and a one year high of $55.51. The firm has a market cap of $20.26 billion, a price-to-earnings ratio of 23.97 and a beta of 1.14. The firm has a 50-day moving average of $40.32 and a 200-day moving average of $43.98.
Mylan (NASDAQ:MYL) last announced its quarterly earnings results on Tuesday, August 9th. The company reported $1.16 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.13 by $0.03. Mylan had a net margin of 8.11% and a return on equity of 23.22%. The company had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.58 billion. During the same quarter in the prior year, the business posted $0.91 EPS. Mylan’s quarterly revenue was up 8.0% on a year-over-year basis. Analysts anticipate that Mylan will post $4.95 EPS for the current year.
In other Mylan news, CEO Heather M. Bresch sold 100,200 shares of the firm’s stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $50.00, for a total value of $5,010,000.00. Following the completion of the sale, the chief executive officer now owns 828,318 shares in the company, valued at approximately $41,415,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.71% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the stock. Wellington Management Group LLP boosted its stake in Mylan by 1.2% in the first quarter. Wellington Management Group LLP now owns 45,335,578 shares of the company’s stock valued at $2,101,304,000 after buying an additional 551,453 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Mylan by 5.7% in the second quarter. Vanguard Group Inc. now owns 26,441,320 shares of the company’s stock valued at $1,143,323,000 after buying an additional 1,431,929 shares in the last quarter. State Street Corp boosted its stake in shares of Mylan by 1.9% in the second quarter. State Street Corp now owns 17,057,413 shares of the company’s stock valued at $737,566,000 after buying an additional 315,552 shares in the last quarter. BlackRock Fund Advisors boosted its stake in shares of Mylan by 11.0% in the second quarter. BlackRock Fund Advisors now owns 12,112,864 shares of the company’s stock valued at $523,760,000 after buying an additional 1,204,050 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in shares of Mylan by 4.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 10,995,727 shares of the company’s stock valued at $475,455,000 after buying an additional 509,821 shares in the last quarter. Hedge funds and other institutional investors own 60.20% of the company’s stock.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan Inc. and related companies with MarketBeat.com's FREE daily email newsletter.